Bioventus INC. (BVS) — SEC Filings

Overview

Bioventus INC. (BVS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 22, 2026: Bioventus Inc. filed its Annual Report to Security Holders (ARS) on April 22, 2026, covering the period ending December 31, 2025. The filing includes a primary ARS document and numerous accompanying graphic files, indicating a comprehensive update for its shareholders.

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 3 bullish, 26 neutral. The dominant filing sentiment for Bioventus INC. is neutral.

Filing Type Overview

Bioventus INC. (BVS) has filed 1 ARS, 2 DEFA14A, 12 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (29)

• Bioventus Files 2025 Annual Report to Security Holders — ARS · Apr 22, 2026 Risk: low
  Bioventus Inc. filed its Annual Report to Security Holders (ARS) on April 22, 2026, covering the period ending December 31, 2025. The filing includes a primary
• DEFA14A Filing — DEFA14A · Apr 22, 2026
• Bioventus Inc. Files 8-K on Officer/Director Changes — 8-K · Nov 17, 2025 Risk: medium
  Bioventus Inc. filed an 8-K on November 17, 2025, reporting events as of November 14, 2025. The filing pertains to the departure of directors or certain officer
• Bioventus Swings to Profit Amidst Sales Dip, Cost Cuts Drive Turnaround — 10-Q · Nov 4, 2025 Risk: medium
  Bioventus Inc. reported a significant turnaround in its financial performance for the nine months ended September 27, 2025, achieving a net income of $9.956 mil
• Bioventus Q2 2025: Equity Shifts Amidst Steady Operations — 10-Q · Aug 6, 2025 Risk: medium
  Bioventus Inc. (BVS) filed its 10-Q for the period ending June 28, 2025, indicating a continued operational period. The filing provides a snapshot of the compan
• Bioventus Inc. Enters Material Definitive Agreement — 8-K · Aug 4, 2025 Risk: medium
  On July 31, 2025, Bioventus Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, headquartered in Durham, Nor
• Bioventus Inc. Files 8-K — 8-K · Jul 31, 2025 Risk: low
  Bioventus Inc. filed an 8-K on July 31, 2025, reporting other events and financial statements as of July 30, 2025. The filing does not contain specific details
• Bioventus Inc. Files 8-K on Security Holder Vote — 8-K · Jun 4, 2025 Risk: low
  Bioventus Inc. filed an 8-K on June 4, 2025, reporting on a matter submitted to a vote of its security holders on June 3, 2025. The filing does not disclose the
• Bioventus Inc. Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
  Bioventus Inc. filed its 10-Q for the period ending March 29, 2025. The filing details financial performance and operational updates for the first quarter of fi
• Bioventus Inc. Files 2024 Definitive Proxy Statement — DEF 14A · Apr 22, 2025 Risk: low
  Bioventus Inc. filed its definitive proxy statement on April 22, 2025, for the fiscal year ending December 31, 2024. The filing, designated as DEF 14A, outlines
• Bioventus Files 2024 Annual Report — 10-K · Mar 11, 2025 Risk: medium
  Bioventus Inc. filed its 10-K for the fiscal year ending December 31, 2024, on March 11, 2025. The company, headquartered in Durham, NC, operates in the surgica
• Bioventus Completes Acquisition — 8-K · Jan 3, 2025 Risk: medium
  Bioventus Inc. reported on December 31, 2024, the completion of an acquisition. The filing also includes financial statements and exhibits related to this event
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• Bioventus Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 5, 2024 Risk: medium
  Bioventus Inc. filed its 10-Q for the period ending September 28, 2024. The filing covers the third quarter and the first nine months of the fiscal year. Key fi
• Bioventus Inc. Files 8-K on Material Agreement — 8-K · Oct 4, 2024 Risk: medium
  Bioventus Inc. filed an 8-K on October 4, 2024, reporting on events as of September 30, 2024. The filing indicates the entry into a material definitive agreemen
• Bioventus Inc. Files 8-K on Financials — 8-K · Aug 6, 2024 Risk: low
  Bioventus Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition, and filing financial statements and exhibits. The
• Bioventus to be Acquired for $1.1 Billion — 8-K · Jul 19, 2024 Risk: medium
  Bioventus Inc. announced on July 19, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Madison Dearborn Partners, LLC. The
• SC 13G/A Filing — SC 13G/A · Jul 15, 2024
• Bioventus Inc. Enters Material Definitive Agreement — 8-K · Jun 21, 2024 Risk: medium
  Bioventus Inc. announced on June 19, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreement,
• Bioventus Inc. Files 8-K on Security Holder Matters — 8-K · Jun 17, 2024 Risk: medium
  Bioventus Inc. filed an 8-K on June 17, 2024, reporting events that occurred on June 11, 2024. The filing indicates material modifications to security holder ri
• Bioventus Inc. Files Proxy Materials — DEFA14A · Jun 3, 2024 Risk: low
  Bioventus Inc. filed a Definitive Additional Materials filing (DEFA14A) on June 3, 2024. This filing relates to the company's proxy statement and indicates no f
• Bioventus Inc. Files 10-Q for Period Ending March 30, 2024 — 10-Q · May 7, 2024 Risk: low
  Bioventus Inc. (BVS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Bioventus Inc. filed a 10-Q report for the period ending March 30, 2024. The f
• Bioventus Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 26, 2024 Risk:
  Bioventus Inc. (BVS) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Bioventus Inc. will hold its Annual Meeting of Stockholders virtually on
• Bioventus Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 12, 2024 Risk: medium
  Bioventus Inc. (BVS) filed a Annual Report (10-K) with the SEC on March 12, 2024. Bioventus Inc. filed its 10-K report for the fiscal year ending December 31, 2
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• AMP-CF Holdings Amends Bioventus Stake as of Dec 31, 2023 — SC 13G/A · Feb 6, 2024
  AMP-CF Holdings, LLC, a major investor in Bioventus Inc. (NASDAQ: BVS), filed an amended Schedule 13G/A on February 6, 2024, updating its ownership stake as of
• EW Healthcare Partners Amends Bioventus Stake Filing — SC 13G/A · Jan 22, 2024
  EW Healthcare Partners Acquisition Fund, L.P. filed an amended Schedule 13G/A on January 22, 2024, indicating their ownership of Bioventus Inc. Class A Common S
• Bioventus Enters Material Definitive Agreement; Details Undisclosed — 8-K · Jan 19, 2024
  Bioventus Inc. filed an 8-K on January 19, 2024, reporting an "Entry into a Material Definitive Agreement" on January 18, 2024. While the filing indicates a sig
• Bioventus 8-K Signals Leadership/Comp Changes on Jan 9 — 8-K · Jan 12, 2024
  Bioventus Inc. filed an 8-K on January 12, 2024, reporting an event that occurred on January 9, 2024, related to the departure or election of directors or offic

Risk Profile

Risk Assessment: Of BVS's 20 recent filings, 0 were flagged as high-risk, 13 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Bioventus INC.'s most recent 10-Q filing (Nov 4, 2025):

• Revenue: $410.187M
• Net Income: $9.956M
• EPS: $0.12
• Debt-to-Equity: 2.39
• Cash Position: $42.164M
• Operating Margin: 8.41%
• Total Assets: $717.743M
• Total Debt: $494.338M

Key Executives

• Robert E. Claypoole

Industry Context

Bioventus operates in the medical device sector, specifically focusing on orthobiologics and regenerative medicine. This industry is characterized by significant R&D investment, stringent regulatory oversight (FDA in the US, and similar bodies globally), and a competitive landscape with both large established players and specialized innovators. Trends include a growing demand for less invasive treatments, advancements in biomaterials, and increasing healthcare costs driving the need for cost-effective solutions.

Top Tags

Bioventus (4) · 10-Q (4) · corporate-governance (4) · financials (4) · Medical Devices (3) · amendment (3) · annual-report (2) · financial-reporting (2) · compensation (2) · Healthcare Sector (2)

Key Numbers

• Documents: 154 — Number of files included in the ARS filing.
• Net Income: $9.956M — Swung from a $46.446M net loss year-over-year for the nine months ended September 27, 2025.
• Net Sales: $410.187M — Decreased by 2.25% from $419.638M for the nine months ended September 27, 2025.
• Operating Income: $34.489M — Improved significantly from a $22.898M operating loss year-over-year for the nine months ended September 27, 2025.
• SG&A Expense: $231.269M — Reduced by $25.656M from $256.925M for the nine months ended September 27, 2025.
• Interest Expense, net: $21.180M — Decreased from $29.795M for the nine months ended September 27, 2025.
• Total Stockholders' Equity: $207.255M — Increased from $185.604M at December 31, 2024.
• Total Liabilities: $494.338M — Decreased from $542.352M at December 31, 2024.
• Cash and Cash Equivalents: $42.164M — Slightly increased from $41.582M at December 31, 2024.
• Diluted EPS: $0.12 — Improved from $(0.56) year-over-year for the nine months ended September 27, 2025.
• Loss on Extinguishment: $326K — Incurred during the nine months ended September 27, 2025, related to debt refinancing.
• Report Period End Date: 2025-06-28 — Latest financial reporting period for Bioventus Inc.
• Filing Date: 2025-08-06 — Date the 10-Q was officially filed with the SEC.
• Form Type: 10-Q — Quarterly report filed by Bioventus Inc.
• SEC File Number: 001-37844 — Unique identifier for Bioventus Inc.'s SEC filings.

Related Companies

BIOV

Frequently Asked Questions